<DOC>
	<DOCNO>NCT01190514</DOCNO>
	<brief_summary>To determine bioequivalence 2 tablet 25 mg sustain release ( SR ) formulation DVS 1 tablet 50 mg SR formulation DVS feed fast condition . To investigate effect high-fat meal pharmacokinetics desvenlafaxine administration 50 mg SR formulation DVS .</brief_summary>
	<brief_title>Phase 1 Study To Test Bioequivalence Between Two 25 mg Tablets vs. One 50 mg Tablet Under Fast/Fed Condition Evaluate Food Effect Desvenlafaxine Succinate Sustained Release ( DVS SR )</brief_title>
	<detailed_description />
	<mesh_term>Depressive Disorder</mesh_term>
	<mesh_term>Depression</mesh_term>
	<mesh_term>Depressive Disorder , Major</mesh_term>
	<mesh_term>Desvenlafaxine Succinate</mesh_term>
	<criteria>Healthy male female subject . Evidence history clinically significant hematological , renal , endocrine , pulmonary , gastrointestinal , cardiovascular , hepatic , psychiatric , neurologic , allergic disease</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>December 2011</verification_date>
	<keyword>DVS SR</keyword>
	<keyword>healthy</keyword>
	<keyword>Bioequivalence study</keyword>
</DOC>